L
ipopolysaccharide represents a major pathogen-associated molecular pattern (PAMP) 3 from the outer membrane of Gram-negative bacteria (1, 2) . It is a potent immune activator closely associated with many infectious and inflammatory diseases (1, 2) . LPS consists of hydrophobic lipid A, the 0-polysaccharide chain, and a core oligosaccharide that may be recognized differently by the host immune system (2-4). The visualization of LPS requires the TLR4 complex and triggers MyD88-dependent and independent signaling pathways (2, 5) . This leads to the activation of NF-B and kinases, including MAPK, ERK1/2, p38, and JNK, which subsequently turn on the expression of many inflammatory genes including NADPH oxidase and inducible NO synthase (4) . Since LPS is a powerful immune activator and may be fatal, the response to LPS must be tightly regulated to maintain the immune response at an appropriate level (6) .
Galectin-3 is a 31-kDa chimeric galectin characterized by a single C-terminal carbohydrate recognition domain (CRD) for carbohydrate binding and an N-terminal aggregating domain that interacts with a noncarbohydrate ligand and allows the formation of oligomers (7, 8) . It is predominantly expressed by innate cells including macrophages and is closely associated with inflammatory responses and cellular functions (9) . It mainly exists in the cytosol due to the lack of a leader sequence, and it is involved in many cellular events (e.g., apoptosis) (10) . However, galectin-3 can also be externalized through a nonclassical transport pathway (11) . As an extracellular protein, it may interact with glycoproteins within the extracellular matrix to form a glycoprotein lattice or act as a soluble ligand to crosslink with the carbohydrates of surface proteins by N-terminal oligomerization, thus evoking signal transduction and cell functions (10 -14) . Mice lacking galectin-3 develop a dominant Th1 phenotype and exhibit abnormalities in several inflammatory disease models including asthma and diabetes, suggesting that galectin-3 may be involved in the regulation of inflammatory and Th1 responses (15) (16) (17) (18) .
␤-galactoside carbohydrates are common structures on many pathogens (19) . It has been suggested that galectin-3 may serve as a pathogen pattern recognition receptor to visualize PAMPs from bacteria (19, 20) , parasites (21, 22) , and fungi (23, 24) . Moreover, it has been reported that galectin-3 interacts with LPS via both NЈ and CЈ terminals (25) . However, the immunological and pathophysiological significance related to these interactions has not been explored.
Data presented herein demonstrate that galectin-3 is a negative regulator for LPS function. Macrophages spontaneously express galectin-3, which specifically binds to LPS. Macrophages from galectin-3-deficient mice have elevated inflammatory cytokine production in response to LPS and lipid A compared with wildtype cells. This is accompanied by an increased phosphorylation of JNK, p38, ERK, and NF-Bp65. The increased inflammatory cytokine production by galectin-3 knockout cells could be normalized by recombinant galectin-3 protein. In vivo, mice lacking galectin-3 excessively produced inflammatory cytokines and NO and were more susceptible to LPS shock. On the other hand, such mice were more resistant to Salmonella infection due to the skewing of a Th1 response and increasing the levels of NO and hydrogen peroxide. Thus, galectin-3 is a novel natural negative regulator for LPS function, which protects against endotoxic shock but may be detrimental by helping in early Salmonella infection.
Materials and Methods
Mice and reagents C57BL/6 mice were purchased from Harlan U.K. Galectin-3 Ϫ/Ϫ mice were generated as described previously (16) . All mice were maintained at the Biological Services Facilities of the University of Glasgow under U.K. Home Office guidelines. Polymyxin B and ␤-lactose, LPS from Escherichia coli 0111:B4, LPS (Re) from Salmonella minnesota Re 595, lipid A, and peptidoglycan (PGN) were purchased from SigmaAldrich. TLR agonists bacterial lipopeptide (BLP, Pam3Cys-SK4), poly(I:C), flagellin and R848 were from InvivoGen. Recombinant murine galectin-3, anti-galectin-3 Ab, and ELISA kit were obtained from R&D Systems. ELISA kits for cytokines, IL-12, IL-6, and TNF-␣ were from BD Biosciences.
The generation of bone marrow macrophages and culture
Bone marrow-derived macrophages (BMMs) were generated as before (26) . RPMI 1640 medium (Invitrogen) containing 10% FCS, penicillin/ streptomycin, and glutamine (complete medium) were used for cell culture. Briefly, femurs were flushed with complete medium, and cells were plated in complete medium containing 10 4 U/ml recombinant human CSF-1 on 10-cm bacteriological plastic plates (Bibby Sterilin) for 7 days in a 37°C incubator containing 5% CO 2 . In some experiments, 20% L929 cell-conditioned medium was used as a source of CSF-1 instead of recombinant human CSF-1. For in vitro macrophage activation, BMMs were plated in 24-well plates at 1 ϫ 10 6 cells/well in 1 ml complete medium plus CSF-1 overnight. The cells were then treated with LPS or different TLR ligands for 8 h, and the cytokines produced in the supernatants were determined by ELISA.
Binding assay
Two methods were used for the study of galectin-3 (R&D Systems) binding to E. coli LPS. ELISA plates (96-well) were coated overnight with LPS (50 g/ml) (see Fig. 3A ) or with recombinant galectin-3 (20 g/ml) or PBS as a control in triplicates (see Fig. 3E ). The plate was then washed and blocked with 10% FCS for 1 h at 37°C. In Fig. 3A , different doses of recombinant galectin-3 were added. In some wells, the galectin-3 was preincubated with anti-galectin-3 Ab or control IgG (2 g/ml) for 30 min before being added into the wells. The samples were incubated for 2 h at 37°C, washed thoroughly, and reincubated with biotinylated anti-galectin-3 Ab (1 g/ml). For Fig. 3E , different doses of biotinylated LPS (InvivoGen) were added for 1 h. ExtrAvidin peroxidase (2 g/ml) was then added for 1 h followed by tetramethylbenzidine substrate. The plate was read using an ELISA reader at 630 nm.
Flow cytometric analysis
BMMs (1 ϫ 10 6 cells/tube) were harvested and blocked with Fc block (5 g/ml) for 30 min. For surface staining, the conjugated anti-galectin-3, CD14-FITC, TLR4-PE, or isotype control Abs were then added and incubated for 30 min at 4°C. For intracellular galectin-3 staining, the cells were fixed with Cytofix/Cytoperm buffer (BD Biosciences), permeabilized with Perm/Wash buffer (BD Biosciences), and incubated with PE-conjugated anti-galectin-3 or isotype controls. Cells were then washed in FACS buffer (1ϫ PBS supplemented with 2% FCS, 0.1% sodium azide) before being analyzed on a FACSCalibur flow cytometer (BD Biosciences).
Western blots
BMMs were stimulated with LPS or LPS (Re) for different times. The cytoplasmic and nuclear proteins were extracted by using a nuclear extract kit (Active Motif). The proteins were separated on 12% SDS-PAGE and transferred onto polyvinylidene difluoride membrane followed by incubation with Abs specific for phosphorylated (P) p65, p38, JNK1/2, ERK1/2, and nonphosphorylated p65, p38, JNK1/2, and ERK1/2 as loading controls (Cell Signaling Technology).
Immunofluorescence and confocal microscopy
BMMs were grown on culture slides and then stained for galectin-3 or TLR4 using specific conjugated Abs. Cells were analyzed with a Zeiss Axiovert microscope using a FITC and Texas Red specific filter set (Glen Spectra).
Fresh overnight cultures of Salmonella-GFP strain were washed once in distilled water and heat fixed on polylysine slides. Fixed Salmonella-GFP were preincubated with PBS or 5 g of galectin-3 (Affinity BioReagents) on slides for 30 min, then incubated with anti-galectin-3 Ab (5 g/ml) or IgG control, followed by anti-mouse Ig-Cy3 (1/200 dilution, SigmaAldrich) for 30 min and visualized by confocal microscopy.
LPS shock
Age-and sex-matched galectin-3 Ϫ/Ϫ and control C57BL/6 mice (n ϭ 10/ group) were injected i.p. with LPS (23 mg/kg body weight). Animals were observed every 6 h for general health. Experiments were terminated on day 5 after LPS injection, as required by the guidelines for animal experimentation (Home Office, London, U.K.). Blood samples were taken from tail vein at indicated times. Serum NO production was quantified by the measurement of the accumulation of nitrite levels using a Griess reagent kit (Biotium) and cytokines produced by ELISA.
Salmonella infection in vivo
Attenuated Salmonella BRD509 (aroA Ϫ aroD Ϫ ) strain was cultured as before (27, 28) . Groups of female galectin-3 Ϫ/Ϫ or wild-type mice were infected orally with 1 ϫ 10 9 live bacteria in PBS (27) . Mice were observed daily for up to 16 days. The mice were culled at different time points. The serum was taken and NO levels were determined by the Griess method, H 2 O 2 by a peroxide assay kit (Pierce), and galectin-3 by ELISA. The spleens, livers, and lymph nodes of the mesentery were removed and homogenized. The serially diluted homogenates were put Med LPS Gal3 * *
Gal 3 (pg/ml)
-/ -FIGURE 1. BMMs coexpress galectin-3, TLR4, and CD14. BMMs from WT and galectin-3 Ϫ/Ϫ (Gal3 Ϫ/Ϫ ) mice were generated as described (48). A, The cells were stained for surface CD14 then permeabilized and stained for intracellular galectin-3 using specific Abs and detected by FACS. B, The surface TLR4 and CD14 levels on WT and Gal3 Ϫ/Ϫ cells were detected by FACS. C, Cells were double stained with anti-TLR4-Texas Red and anti-galectin-3-FITC and visualized by immunofluorescence microscopy. D, WT and Gal3 Ϫ/Ϫ BMMs (1 ϫ 10 6 /ml) were cultured with or without LPS (1 g/ml) for indicated times, and secreted galectin-3 was detected by ELISA. The results represent one of three independent experiments.
onto Luria-Bertani agar plates in triplicates and incubated at 37°C overnight. The numbers of bacteria were counted and expressed as CFU/ organ. The spleen and draining lymph node cells were cultured in 24-well plates at 2 ϫ 10 6 cells/ml complete medium and treated with medium alone or with different doses of Salmonella Ags (bacteria were lysed by freezing at Ϫ70°C and thawing out at 37°C for at least three cycles) for 48 and 72 h. The supernatants were collected and cytokine profile was determined by ELISA using paired Abs.
Statistical analysis
Statistical analysis was performed using Minitab software. For in vivo trials, the two-tailed log-rank test was used, and Student's t test was used for analysis of cytokine concentrations. Statistical significance was accepted at p Ͻ 0.05.
Results

Primary macrophages coexpress galectin-3 with TLR4 and CD14
Galectin-3 was originally identified on macrophages as a macrophage surface Ag (7). However, its role in these cells is not fully understood. First, we sought to systemically study the expression and localization of galectin-3 BMMs. These primary macrophages were generated from wild-type (WT) and galectin-3 Ϫ/Ϫ mice and the expression of galectin-3 was determined. CD14
ϩ BMMs from WT but not galectin-3 Ϫ/Ϫ mice constitutively expressed intracellular galectin-3 detected by flow cytometry using a specific Ab (Fig. 1A) . Since TLR4 and CD14 are the important components in the LPS receptor complex, we established that galectin-3 Ϫ/Ϫ expressed similar levels of TLR4 and CD14 as did the WT cells (Fig.  1B) . Immunofluorescence microscopy showed the coexpression of galectin-3 with TLR4 on BMMs (Fig. 1C) . Furthermore, BMMs from WT but not galectin-3 Ϫ/Ϫ mice also spontaneously secreted galectin-3 detected within 2 h after culture and were further enhanced in a time-dependent manner (Fig. 1D) . Interestingly, the galectin-3 production could be significantly increased 2-4 h after LPS stimulation (Fig. 1D ).
Exaggerated inflammatory cytokine production by galectin-3 Ϫ/Ϫ
BMMs in response to LPS and lipid A
To define the role of galectin-3 as a pathogen pattern recognition receptor and the immunological significance related to the interplay between galectin-3 and LPS, we tested the effects of several well-documented TLR agonists on galectin-3 Ϫ/Ϫ and WT BMMs: LPS (E. coli 0111:B4) and lipid A for TLR4, bacteria BLP and PGN for TLR2, poly(I:C) for TLR3, flagellin for TLR5, and R848 for TLR7 and TLR8. BMMs (1 ϫ 10 6 /ml/well) were rested on 24-well plates overnight before being activated with different TLR ligands directly without washing. As illustrated in Fig. 2A , these TLR agonists induced the expected levels of IL-12, IL-6, and TNF-␣ production from WT BMMs. However, LPS-stimulated galectin-3 Ϫ/Ϫ cells exaggerated this and markedly increased amounts of all inflammatory cytokines tested compared with WT controls (Fig. 2A) . It was noted that the cytokines induced by TLR2 agonists, BLP and PGN were selectively affected in galectin-3-null cells, since only IL-6 but not IL-12 and TNF-␣ production was significantly enhanced (Fig. 2A) . In contrast, galectin-3 deficiency had no significant influence on the effect of other tested TLR ligands ( Fig. 2A) . We further assessed the role of galectin-3 on LPS and its derivative LPS (Re) from rough strain (lacking 0-polysaccharide) of Salmonella and lipid A. BMMs from WT and galectin-3 Ϫ/Ϫ mice were cultured overnight as above and stimulated with graded doses of LPS, LPS (Re), or lipid A directly without washing for 8 h. As illustrated in Fig. 2B , compared with WT, galectin-3 Ϫ/Ϫ BMMs exhibited exaggerated response to LPS, LPS (Re), and lipid A and produced significantly higher amounts of IL-12, IL-6, and TNF-␣ in a dose-dependent manner. No significant changes in the IL-10 and TGF-␤ production had been detected between WT and galectin-3 Ϫ/Ϫ BMMs (data not shown). Thus, our results demonstrate that galectin-3 is a novel regulator that mainly controls the response to TLR4 ligands and, partially, TLR2 ligands.
Galectin-3 binds to LPS and blocks LPS-induced inflammatory cytokine production
The results from galectin-3-deficient cells (Fig. 2) reveal an apparent modulatory role of this molecule for LPS responsiveness. To investigate whether galectin-3 affects LPS function by binding to LPS as suggested before (25), using two different binding assays, we confirmed that galectin-3 bound to LPS (Fig.  3, A and E) . Importantly, this binding could be specifically abolished by the preincubation of galectin-3 with anti-galectin-3 Ab but not control IgG (Fig. 3A) . To determine whether the interaction between galectin-3 and LPS could affect LPS-induced inflammatory cytokine production, the LPS or lipid A was pretreated with different doses of recombinant galectin-3 for 30 min before being added into the overnight cultured galectin-3 Ϫ/Ϫ BMMs, and the subsequent cytokine production was measured as illustrated (Fig. 3B) . The WT and galectin-3 Ϫ/Ϫ BMMs cultured in the presence or absence of LPS or lipid A were also included as controls. As noted previously, galectin-3 Ϫ/Ϫ cells had exaggerated IL-12, IL-6, and TNF-␣ production in response to LPS or lipid A compared with WT cells. The increased effect was significantly reduced by the preincubation of LPS or lipid A with galectin-3 in a dose-dependent manner (Fig. 3B) . Reversely, pre-adding neutralizing anti-galectin-3 Ab but not control IgG into the WT BMMs culture significantly enhanced LPS-induced IL-12, IL-6, and TNF-␣ production (Fig. 3C) . Furthermore, it was noted that LPS elicited a less significant increase in inflammatory cytokine production when the galectin-3 containing supernatants from overnight cultured WT BMMs were replaced with fresh medium before adding LPS, suggesting that both secreted and surface galectin-3 contribute to the regulatory effect (data not shown). Thus, our results suggest that galectin-3 inhibits LPS and lipid A function through a direct interaction.
Structurally, the N-terminal of galectin-3 binds to lipid A and the C-terminal CRD binds to the ␤-galactoside of LPS (25) . Therefore, it is possible that galectin-3 blocks LPS function via both sites. BMMs lacking galectin-3 were hypersensitive to lipid A, which lacks ␤-galactoside, suggesting that the N-terminal of galectin-3 has a regulatory effect on LPS (Figs. 2B and 3B ). min to block the C-terminal carbohydrate-binding sites of galectin-3 before adding LPS and culturing the cells for 8 h.
Preincubating with ␤-lactose dramatically increased the LPS-induced inflammatory cytokines, IL-12, IL-6, and TNF-␣ production by WT BMMs in a dose-dependent fashion (Fig. 3D) . Therefore, our data suggest that galectin-3 may suppress LPS function by interacting with LPS via lipid A and/or ␤-lactose motifs using N-terminal nonlectin and/or C-terminal lectin domain, respectively. Polymyxin B neutralizes LPS activity by binding to the lipid A domain, which also blocks the interaction between LPS and galectin-3 (25, 29) . Preincubation of LPS and lipid A with polymyxin B almost completely abolished their effect on galectin-3
BMMs (data not shown), confirming that the effects observed by LPS on galectin-3 Ϫ/Ϫ BMMs are specific.
Galectin-3 affects LPS function by sequestrating LPS signaling
We further investigated whether the enhanced inflammatory cytokine production by galectin-3 Ϫ/Ϫ cells is due to accelerated LPS signaling. WT and galectin-3 Ϫ/Ϫ BMMs were activated as indicated (Fig. 4, A and B) . The LPS-induced phosphorylation of JNK1/2, ERK1/2, p38, and NF-Bp65 was more persistent, and JNK1/2 appeared earlier and stronger in galectin-3 Ϫ/Ϫ BMMs than that in WT cells (Fig. 4A) . It was also the case in the LPS (Re)-stimulated cells (Fig. 4B) , which is consistent with the inflammatory cytokine profile (Fig. 2B) . Importantly, the enhanced phosphorylation of JNK1/2, ERK1/2, p38, and NF-Bp65 by LPS in galectin-3 Ϫ/Ϫ cells could be normalized by adding recombinant galectin-3 (Fig. 4C) . Thus, galectin-3 affects LPS function by 4. Galectin-3 affects LPS function by sequestrating LPS signaling. BMMs were activated with LPS (0.1 g/ml) (A) or LPS (Re) (0.5 g/ ml) (B) for indicated times. Cytosol proteins were separated and the levels of phosphorylated (P) JNK1/2, ERK1/2, p38, p65, and nonphosphorylated JNK1/2, ERK1/2, p38, and p65 (loading control) were detected by Western blot using specific Abs. C, BMMs were incubated with or without galectin-3 (500 ng/ml) for 30 min and activated with LPS for indicated times. The cytosol proteins were isolated and Western blot performed as in A and B.
binding to the molecule and subsequently interfering with its signaling cascades.
Galectin-3
Ϫ/Ϫ mice are more susceptible to endotoxin shock Endotoxin shock is the most severe form of LPS-mediated inflammatory disease. The in vitro results above encouraged us to further explore the in vivo effect of galectin-3 in a shock model. WT and galectin-3 Ϫ/Ϫ mice were given a minimal lethal dose of LPS. The development of shock syndrome and mortality were monitored at regular intervals. Galectin-3 Ϫ/Ϫ mice were more susceptible to LPS-induced shock compared with the controls. No mice survived in the galectin-3 Ϫ/Ϫ group 25 h post-LPS challenge, while 70% of WT mice were still alive (Fig. 5A) . Forty percent of the WT mice eventually completely recovered (Fig. 5A ). NO and TNF-␣ are critically involved in LPS shock (30, 31) . We noted that galectin-3 Ϫ/Ϫ mice produced more serum nitrite than did WT mice, and the levels of nitrite were further increased after LPS injection (Fig.  5C ). Consistent with these in vitro findings (Fig. 2) , the elevated mortality rate in galectin-3 Ϫ/Ϫ mice was also accompanied by the significantly enhanced serum TNF-␣ levels 4 h after LPS challenge (Fig. 5D ). As observed in vitro (Fig. 1D) , LPS also induced high levels of serum galectin-3 in WT but not in galectin-3 Ϫ/Ϫ mice, indicating that the induction of galectin-3 may be involved in a feedback regulation of the LPS-mediated inflammatory response (Fig. 5B) .
Ϫ/Ϫ mice are highly resistant to Salmonella infection LPS is a major PAMP of Salmonella and plays a critical role in salmonellosis (1, 2, 32) . To further understand the in vivo regulatory role of galectin-3 in LPS function, we next evaluated its role in Salmonella infection. First, we found that galectin-3 binds to Salmonella (Fig. 6A) , suggesting that galectin-3 may play a direct role in Salmonella-mediated infection. To test its role in vivo, the galectin-3 Ϫ/Ϫ and WT control mice were infected orally with Salmonella typhimurium as described (27, 28) . Salmonella replicated gradually in the organs of WT mice, which peaked at day 10, then declined and were completely eliminated from the organs after 20 days of infection (Fig. 6B) . By contrast, in galectin-3 Ϫ/Ϫ mice, the bacteria replicated poorly, showing dramatically reduced bacterial burdens in all organs tested, especially in the spleen and draining lymph node compared with that of WT mice (Fig. 6B) . We found that there was no clear difference in the bacterial uptake and viability between the galectin-3 Ϫ/Ϫ and WT BMMs (data not shown), suggesting that the reduced bacterial numbers in galectin-3-deficient mice was not attributed to an attenuated ability of bacterial phagocytosis or an enhanced susceptibility to apoptosis after infection.
It is well known that NO and H 2 O 2 are the major bactericidal reactive oxygen species (ROS) (33, 34) . We noted that galectin-3 Ϫ/Ϫ mice produced more serum nitrite and H 2 O 2 than did WT mice (Fig. 6C) . After Salmonella infection, the serum levels of nitrite and superoxide in galectin-3 Ϫ/Ϫ mice were further enhanced on days 5 and 8 compared with WT mice (Fig. 6C) . Importantly, the magnitude of NO and H 2 O 2 levels was the reciprocal of the bacterial counts in the infected organs of the null and WT mice. In agreement with the LPS shock result (Fig. 5B) , Salmonella infection also elevated serum galectin-3 production (Fig. 6E) , whose levels were correlated with bacteria number in the organs (Fig. 6B) .
A Th1 response and Th1 cytokines IFN-␥ and TNF-␣ are also required by the host to clear Salmonella infections (35, 36) . We further verified the role of Salmonella-induced IFN-␥ and TNF-␣ production in host protection. The draining lymph node and spleen cells from the infected mice were treated with medium alone or Salmonella Ags for 72 h. No significant difference in the T cell proliferation was observed (data not shown). However, 10 days after infection, the draining LN cells from galectin-3 Ϫ/Ϫ mice produced strikingly higher levels of Salmonella-specific IFN-␥ and TNF-␣ than did the cells from WT mice (Fig. 6D) . No significant levels of IL-4, IL-5, and IL-10 were detected in the cultures (data not shown), indicating that galectin-3 Ϫ/Ϫ mice developed an increased Th1 response. The Salmonella-specific Th1-like response was sustained for at least 7 days until the bacterial infection had been eliminated. Interestingly, the levels of Ag-specific Th1 cytokine production from both WT and galectin-3 Ϫ/Ϫ cells were the reciprocal of the organ bacterial load, which indicated that the reduced replication of Salmonella in galectin-3 Ϫ/Ϫ mice may also be due to an elevated protective Th1-type response (Fig. 6, B and D) .
The interaction of galectin-3 with other BMM surface ligands is unlikely to be responsible for its regulatory effect on LPS
It has been reported that galectin-3 also binds to several macrophage membranous proteins, including CD98 and CD13 (37, 38) . To investigate the possibility that galectin-3 may modulate LPS function via alternative interaction with other membrane proteins, galectin-3 Ϫ/Ϫ BMMs were preincubated with recombinant galectin-3 for 1 h, then washed with prewarmed medium or left unwashed before being activated with LPS. We found that removing the unbound galectin-3 from the culture abolished its regulatory effect on LPS, suggesting that crosslinking of galectin-3 with other ligands on BMMs is not responsible for the function of galectin-3 (Fig. 7A) . Furthermore, anti-CD98 or CD13 antibody-treated galectin-3 Ϫ/Ϫ BMMs produced similar levels of cytokines as did the untreated or IgG-treated cells in response to LPS or LPS preincubated with galectin-3 (Fig. 7B) . Additionally, we also found that replacing galectin-3-containing supernatants from overnight-cultured WT BMMs with fresh medium significantly enhanced LPSinduced inflammatory cytokine production by the cells (data not shown). Thus, although the interaction of galectin-3 with other surface ligands is important for macrophage function in some contexts, this is unlikely to be responsible for the regulatory effect of galectin-3 on LPS function in our experimental setting.
Discussion
We have demonstrated herein that galectin-3 directly interacts with LPS and blocks LPS-induced inflammatory response. LPS-stimulated galectin-3 Ϫ/Ϫ macrophages elevated LPS signaling and secreted higher levels of inflammatory cytokines compared with WT cells. This enhanced cytokine profile and signaling by the gene knockout cells could be normalized by recombinant galectin-3 protein. In reverse, blocking galectin-3 with a neutralizing Ab or its high-affinity ligand, ␤-lactose, led to a dramatically increased response to LPS and inflammatory cytokine production by WT macrophages. In vivo, galectin-3 Ϫ/Ϫ mice were more vulnerable to LPS-induced shock, exhibiting a significantly enhanced mortality rate that was accompanied by an elevated profile of proinflammatory cytokines and NO production. Finally, galectin-3 binds to Salmonella. Salmonella-infected galectin-3-deficient mice increased Th1 response and NO burst, which protected the mice against Salmonella infection. Therefore, galectin-3 is a novel repressor and checkpoint for LPS function and LPS-mediated disease.
It is still not entirely known how galectin-3 represses LPS function. Galectin-3 is the only chimera lectin in the family that has a unique ability to interact with both carbohydrate and noncarbohydrate ligands (10) . The lipid A part of LPS is essential for LPSmediated bioactivity, and galectin-3 is capable of interacting with * * * * * * lipid A through its N-terminal (25) . We found that galectin-3 Ϫ/Ϫ cells were hypersensitive to lipid A stimulation (Figs. 2 and 3 ). Therefore, it is possible that galectin-3 blocks LPS function by binding to the lipid A portion of LPS. However, its C-terminal CRD may also contribute to the effect of galectin-3 by binding with ␤-lactose of LPS. Indeed, ␤-lactose, which antagonizes the interaction between galectin-3 and the ␤-lactose of LPS, dramatically enhanced LPS-induced inflammatory cytokine production by the WT macrophage (Fig. 3D) . Therefore, galectin-3 may interfere with LPS function by interacting with LPS via both lipid A and ␤-lactose portions (25) . Since no obvious change has been found in the expression and function of LPS receptor complex related to the galectin-3 deficiency, it is likely that galectin-3 affects LPS function by binding to LPS and subsequently interferes with the interaction of LPS with its receptor complex, thereby repressing the downstream signaling cascades of LPS (Fig. 4) . It is noteworthy that the intracellular, membrane-bound, and secreted galectin-3 may all contribute to LPS regulation but by different mechanisms. The serum galectin-3 may antagonize LPS function during an acute bacterial infection via both N-and Cterminals. The membrane-bound molecule, which is coexpressed with TLR4, could also block LPS function by interacting with the lipid A motif of LPS through its free N-terminal. Moreover, the intracellular galectin-3 may play a critical role in intracellular bacterial infection. Thus, given that it is constantly expressed by all cells in high levels and induced by LPS stimulation, galectin-3 may represent a critical factor against excessive LPS-triggered inflammation.
NO and H 2 O 2 play an important role in inflammation and are the major bactericidal ROS (33) . We noted that galectin-3 Ϫ/Ϫ mice spontaneously produced more serum nitrite and H 2 O 2 than did WT mice (Figs. 5C and 6C). After LPS challenge and Salmonella infection, the serum levels of NO and superoxide in galectin-3 Ϫ/Ϫ mice were further enhanced compared with WT mice (Figs. 5C and 6C). Furthermore, these ROS appeared much earlier than inflammatory cytokine production (Fig. 6, C and D) , further suggesting that galectin-3 may directly modulate NO and superoxide production. Consistent with these observations, LPS and Salmonella also induced increased serum galectin-3 production in WT mice whose kinetic expression was inversely correlated with ROS and inflammatory cytokine production (Figs. 5 and 6 ). However, its production was positively correlated with survival rate in LPS shock and the bacterial load in the Salmonella infection model (Figs. 5 and 6 ). These results further suggest that the purpose of the galectin-3 induced by LPS was to suppress the subsequent inflammatory gene activation, including NO and superoxide production. Whereas the molecular mechanism by which galectin-3 affects NO and superoxide is still unknown, since JNK and p38 are associated with the induction of NO and superoxide (39 -41) and galectin-3 Ϫ/Ϫ cells enhanced LPS-induced JNK and p38 activity (Fig. 4) , it is possible that galectin-3 modulates NO and superoxide by inhibiting these components of TLR4 signaling pathway. More work is needed to clarify this issue.
It is intriguing that mice lacking galectin-3 showed enhanced Th1 skewing during Salmonella infection. This is consistent with other reports that galectin-3 deficiency promotes a predominantly Th1 response (15) (16) (17) (18) . However, the mechanism is not fully understood. Our results may provide an explanation for the preferential induction of inflammatory and Th1 responses in the mice, at least in LPS-mediated responses and Salmonella infection. Since LPS is a potent Th1 inducer by promoting IL-12 production (42), and, consequently, losing the regulation of galectin-3, APCs may become hypersensitive to LPS and produce more IL-12, which ultimately affects the Th1 polarization (43) . Given that LPS is constantly present in the commensal flora and is widely distributed in the environment, this regulatory pathway may be critical for homeostasis during infection and may contribute to the pathogenesis of other inflammatory and Th1-mediated diseases (15) (16) (17) (18) .
The outcome of salmonellosis depends on the interaction between the host and bacteria. Salmonella have evolved the ability to escape immune surveillance and expand in the host (44, 45) . Our results demonstrate that galectin-3 is required for the improved survival of Salmonella in vivo via at least two mechanisms: first, by suppressing ROS release, and second, by inhibiting Th1 responses. While the detailed mechanism is still unresolved, the regulatory role of galectin-3 in Salmonella infection may be in addition to its binding of LPS, since it also partially modulates TLR2 function ( Fig. 2A) . BLP and PGN are abundantly produced by all bacteria and are important PAMPs in bacterial-mediated diseases, including salmonellosis (46, 47) . It is unclear at present why galectin-3 selectively modulates some but not all TLR agonists' function. Since LPS contains the ligands for galectin-3, it is likely that only the microbial product that expresses galectin-3 ligand can be regulated. This hypothesis is under investigation. Nevertheless, it is likely that bacteria utilize host galectin-3 to mask their surface danger signals, LPS, and perhaps BLP and PGN as well, thereby silencing the immune system and allowing Salmonella to multiply. Thus, galectin-3 may play an important role in host-bacteria interaction and may be a new target for therapeutic interventions in bacteria infections. Finally, ␤-galactosides are common surface components associated with many infectious agents, and as such will be important to determine what role galectin-3 may play in other infections.
